Bobby Tullos, MD
Pulmonary Disease · Gulfport, MSNPI 1841554250
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $172,357 of the $276,456 with a category attached, or 62.3%. 60 manufacturers reported payments, led by GSK at 51.4% of the total. Among pulmonary disease clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,164 payments — averaging $237.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$142K
- Intuitive Surgical$34K
- Mylan Specialty L.p.$32K
- Olympus America Inc.$20K
- United Therapeutics Corporation$19K
- Pinnacle Biologics, Inc$5K
- plus $26K from 54 others
Across 89 payments — averaging $949.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$68K
- Boehringer Ingelheim International GmbH$16K
What the payments were for
- Consulting fees$28,68610%
- Speaking & faculty fees$172,35762%
- Travel & lodging$20,1847%
- Food & beverage$27,53410%
- Education$27,69510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$80,086
- Da Vinci Surgical System$33,291
- Yupelri$30,546
- Spiration Valve System$18,039
- TYVASO$10,600
- Photofrin$4,517
- DUPIXENT$3,564
- AREXVY$2,600
- Single-Use flexible Video Bronchoscope$2,150
- Spin$1,885
- FASENRA$361
- BREZTRI$259
- PURIFIED CORTROPHIN GEL$172
- PT101US/Airvo 2$121
- OPT944/Optiflow Nasal Cannula$121
- OPT1044/Optiflow 3S Nasal Cannula$121
- 900PT561/Airvo 2 Air Spiral Tube/Chamber Kit$121
- OPT970/Optiflow Tracheostomy Interface$121
- UPTRAVI$114
- OPSUMIT$114
How this compares
$276,456 in reported general payments places this provider in the 95th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 61 | $791,480 |
| Tyvaso DpiTreprostinil | 19 | $444,453 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 342 | $270,563 |
| AdempasRiociguat | 12 | $169,052 |
| TezspireTezepelumab-Ekko | 23 | $110,648 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 120 | $93,193 |
| Fasenra PenBenralizumab | 14 | $78,969 |
| Dupixent SyringeDupilumab | 14 | $56,773 |
| Dupixent PenDupilumab | 14 | $53,062 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 75 | $43,066 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 48 | $23,586 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $21,985 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $15,166 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 213 | $6,497 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,248 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat | $2,541 | $839,793147 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $141,978 | $316,135443 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $3,056 | $219,007180 claims |
| BayerAdempas | $230 | $169,05212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Gulfport
- Frederick PakronGulfport$7K
- William FrazierCanton$809K
- Demondes HaynesJackson$809K
- Michal SenitkoJackson$185K
- Cameron HuxfordStarkville$155K
- L AldredHattiesburg$76K
- Andrew WilhelmJackson$51K
- Raymond PortisJackson$39K
- Jaime UngoTupelo$29K
- Olukunle AjagbeMcComb$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.